Skye Bioscience Inc's Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including federal healthcare benefit programs and Medicaid. It operates within regulatory frameworks that address marketing products for unapproved uses, fraud and abuse statutes, and compliance with federal and state laws. Its market segments include federal health programs, Medicaid, private third-party payors, physicians, teaching hospitals, and other healthcare providers. Manufacturers of covered drugs are required to report payments and transfers of value to physicians and teaching hospitals under the Patient Protection and Affordable Care Act and related state regulations. The company also adheres to obligations under the Health Insurance Portability and Accountability Act (HIPAA) and the Health Information Technology for Economic and Clinical Health Act (HITECH), which govern the privacy and security of protected health information and affect business associates providing services to covered entities.
In the dynamic sphere of pharmaceutical sciences, the continual pursuit of innovative therapeutic innovations remains pivotal for alleviating global health issues. Substantial strides have been made through biotechnological advancements in diagnosing and treating diverse spectrums of diseases. One such pioneering effort is visible in the endeavors of Skye Bioscience Inc., a devoted pharmaceutical company crafting medicines targeting the endocannabinoid system. This article explores Skye s commitment to providing promising solutions for ocular diseases such as dry eye disease, chronic ocular pain, primary open-angle glaucoma (POAG), and ocular hypertension (OHT).At ARVO 2024 Annual Meeting, Skye Bioscience pr...
In a recent announcement, Skye Bioscience, Inc. revealed that it will be presenting two posters at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting taking place from May 5th to 9th in Seattle, Washington. Skye Bioscience, a clinical-stage biotechnology company specializing in the development of therapeutic drugs targeting the endocannabinoid system, aims to revolutionize treatment options for ocular disorders and vision-related conditions.:This article seeks to provide an overview of Skye Bioscience s upcoming participation at ARVO 2024. By synthesizing the available information, we aim to outline the significance of the company s contributions in the field of vision and op...
Skye Bioscience, a pharmaceutical company specializing in targeting the endocannabinoid system, recently announced that it has treated the first patient in its Phase 2 clinical trial for SBI-100 Ophthalmic Emulsion (OE). This trial aims to evaluate the emulsion s ability to lower intraocular pressure (IOP), its safety profile, and relevant biomarkers in patients suffering from primary open-angle glaucoma (POAG) or ocular hypertension (OHT). Glaucoma is a leading cause of irreversible blindness worldwide, affecting more than 76 million people. It is characterized by progressive damage to the optic nerve, often due to increased IOP. Currently available treatments for glaucoma aim to reduce IOP, as lowering...
Skye Bioscience Inc’s Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including federal healthcare benefit programs and Medicaid. It operates within regulatory frameworks that address marketing products for unapproved uses, fraud and abuse statutes, and compliance with federal and state laws. Its market segments include federal health programs, Medicaid, private third-party payors, physicians, teaching hospitals, and other healthcare providers. Manufacturers of covered drugs are required to report payments and transfers of value to physicians and teaching hospitals under the Patient Protection and Affordable Care Act and related state regulations. The company also adheres to obligations under the Health Insurance Portability and Accountability Act (HIPAA) and the Health Information Technology for Economic and Clinical Health Act (HITECH), which govern the privacy and security of protected health information and affect business associates providing services to covered entities.
Sources:
Skye Bioscience Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Skye Bioscience Inc’s corporate clients.
For your research, we’ve provided 9 tables on Skye Bioscience Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
